GlassScriptPhysician profile
Mai Thao Pham
NPI 1902251317
$2,982.06
in general payments reported to CMS, 2019-2025
24 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $967 · 2021: $880 · 2022: $374 · 2023: $247 · 2024: $16.51 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $723.75 | 2019-2023 | Breztri |
| Novo Nordisk INC | $407.24 | 2020-2021 | |
| Lilly USA, LLC | $234.27 | 2020-2024 | Jardiance |
| Stryker Corporation | $204.91 | 2021-2023 | Variax |
| Merck Sharp & Dohme LLC | $142.97 | 2019-2023 | Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.19 | 2020-2021 | |
| Eisai INC. | $122.81 | 2020-2021 | |
| Treace Medical Concepts, INC. | $109.14 | 2025 | |
| Janssen Scientific Affairs, LLC | $109.08 | 2022 | |
| Abbvie INC. | $99.71 | 2022 | |
| Pfizer INC. | $88.90 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $88.05 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $75.22 | 2020-2021 | |
| Kerecis Limited | $72.56 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Corium, LLC | $70.70 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.17 | 2021-2022 | |
| Gilead Sciences, INC. | $53.30 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $50.55 | 2019-2021 | |
| Genentech USA, INC. | $34.76 | 2020-2021 | |
| Amgen INC. | $24.02 | 2021 | |
| Glaxosmithkline, LLC. | $21.05 | 2021 | |
| Incyte Corporation | $20.50 | 2025 | Jakafi |
| Astellas Pharma US INC | $17.19 | 2021 | |
| Smith+Nephew, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mai Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.